<DOC>
	<DOCNO>NCT01381796</DOCNO>
	<brief_summary>The purpose research : 1 . Compare two study patch minor difference patch component 2 . Compare pharmacokinetics ( PK - body absorbs , metabolize eliminates medication ) NP101 ( study patch ) versus currently approve oral formulation Imitrex 3 . Collect resistance data application NP101 ( study patch )</brief_summary>
	<brief_title>Compare PK Bioavailability 2 NP101 Patches With Oral Imitrex Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Healthy adult male female subject , age 18 65 year , time screen . Subject judge good health , base upon result medical history , physical examination , vital sign , ECG laboratory profile . Subjects clinically significant abnormal laboratory parameter , vital sign ECG parameter order qualify enrollment . Subject must capable read understand English Spanish , able carryout study procedure , voluntarily sign date inform consent ( IC ) agreement approve IRB . Subject must negative drug screen . Subject two acceptable patch application site ( leave and/or right upper arm ) relatively hair free scar , tattoo , scratch bruise . Subjects must body mass index 18 25 kg/m2 inclusive . Subjects must nonsmoker , define use tobacco product 6 month screen . Subjects must consume alcoholic beverage , poppy seed , grapefruit , and/or grapefruit juice within 72 hour prior admission clinic Period 1 duration study . Subjects must adequately inform nature risk study give write informed consent prior screen . The subject must likely complete entire study . Subject suspect confirm cardiovascular disease contraindicates study participation . Subject history epilepsy condition associate lowered seizure threshold . Subject Raynaud 's disease . Subject history basilar hemiplegic migraine . Subject current diagnosis major depressive disorder per Diagnostic Statistical Manual Mental Disorders version 4 revise ( DSMIVR ) . Subject take nontriptan serotonergic drug include selective serotonin reuptake inhibitor ( SSRIs ) , serotonin norepinephrine reuptake inhibitor ( SNRIs , include Wellbutrin ) , tricyclic antidepressant ( TCAs ) , monoamine oxidase inhibitor ( MAOIs ) preparation contain St. Joh 's Wort within 1 month prior screen and/or plan start medication study End Study visit . Subject unwilling discontinue use phosphodiesterase type 5 inhibitor ( e.g . Viagra , Levitra , Cialis ) screen End Study visit . Subject history significant allergy hypersensitivity component study patch use study ( NP101 formulation detail find NP101 Investigator Brochure ) . Subject generalized skin irritation disease include eczema , psoriasis , melanoma , acne contact dermatitis . Subject positive hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) . Subject hepatic dysfunction define SGOT/AST SGPT/ALT great equal 2 time upper limit normal ( ULN ) range , alkaline phosphatase total bilirubin great equal 1.5 time ULN range opinion Investigator subject 's history , physical examination laboratory test suggest hepatic dysfunction . Female subject pregnant , breast feeding , childbearing potential , use unwilling use effective form contraception study period 30 day follow final dosing . Acceptable method contraception include barrier method spermicide , intrauterine device ( IUD ) , steroidal contraceptive ( oral , transdermal , implanted inject ) abstinence . If exclusive male partner surgically sterile , acceptable . Subject known history tolerability issue sumatriptan . Subject consider investigator NuPathe , reason , unsuitable candidate study . Subject history ( within 1 year ) current evidence drug alcohol abuse dependence . Subject participate clinical study within 30 day screen . Subject clinically significant abnormal laboratory parameter , vial sign ECG parameter . Subject electrically sensitive ( e.g. , prior iontophoresis adverse outcome relate current deliver device ) implantable electronic device ( e.g. , pacemaker ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>